Sanofi wins US approval for multiple myeloma drug in newly …
WEBSept 20 - The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's (SASY.PA) Sarclisa infusion as a treatment for certain types of ...
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
WEB4 days ago — Sarclisa made around $413 million in sales for Sanofi last year, a fraction of the $9.7 billion booked by J&J for Darzalex, so having a niche free of competition from its rival could translate to ...
Press Room - Sanofi US News
WEBSep 20, 2024 — The US Food and Drug Administration (FDA) has approved SARCLISA (isatuximab-irfc) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).
FDA Approves Sarclisa with VRd | Int'l Myeloma Foundation
WEBAccording to a September 20, 2024, press release, the U.S. Food and Drug Administration (FDA) has "approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT)." This approval was based on results of the phase III IMROZ clinical trial ...
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma ...
WEB4 days ago — On Saturday, the FDA approved Sanofi’s SA (NASDAQ:SNY) Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult ...
Press Release: Sarclisa approved in the US as the first anti-CD38 ...
WEBSep 20, 2024 — The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
WEBJun 3, 2024 — Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Press Room - Sanofi US News
WEBAug 8, 2024 — Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant.
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
WEB4 days ago — REGN. Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in ...
Sanofi Induction Therapy Improves PFS | Int'l Myeloma Fndtn
WEBAug 9, 2024 — Sarclisa Induction Therapy Shows Promise in Transplant-Eligible, Newly Diagnosed Multiple Myeloma. According to an August 8, 2024, Sanofi press release, "Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant."
- Some results have been removed